USPatent applicationPatented

Stabilization of radiosynthetic intermediates

Granted 24 Oct 2017 · 2 office actions

Life of the application

11 dated events
⤢ drag to zoom20152020202520302035ProsecutionOwnershipTerm & fees
ProsecutionOwnershipTerm & feeshover for detail · click to open

Abstract

The present invention relates to a method for stabilizing radiosynthetic intermediates used in synthesis of 18 F radiolabeled aromatic amino acid derivatives toward decomposition caused by beta and gamma radiations by the use of radical scavengers and/or reductants and/or antioxidants.

Description

14 parts
›FIELD OF THE INVENTION

The present invention relates to methods for the synthesis of 18 F radiolabeled aromatic amino acid derivatives and more particularly to a method for stabilizing the radiosynthetic intermediates used in said methods toward their decomposition caused by beta and gamma radiations.

›BACKGROUND ART

Positron Emission Tomography

Positron emission tomography (PET) is an imaging method for obtaining quantitative molecular and biochemical information of physiological processes in the body. The most common PET radiotracer in use today is [18F]-fluorodeoxyglucose ([18F]-FDG), a radiolabeled glucose molecule. PET imaging with [18F]-FDG allows to visualize glucose metabolism and has a broad range of clinical indications. Other PET radiotracers are about to enter the clinical use. Among positron emitters, 18 F is the most widely used today in the clinical environment.

Decomposition of Radiochemicals—Radiolysis

Radiotracers are obtained after single or multiple step organic synthesis, among which the fluorination with 18 F-fluorides. radiosynthetic intermediates are generally involved in such radiosyntheses. These radiosynthetic intermediates can be exposed to high levels of radioactivity and high dose rates which results in some decomposition processes commonly named radiolysis. These side reactions can consume those radiosynthetic intermediates or react with the 18 F-fluorides and are detrimental to having high radiochemical yields.

The modes by which radiosynthetic intermediates decompose and their corresponding methods of control were classified in 1960 (Bayly, R. J. and Weigel, H., Self-decomposition of compounds labeled with radioactive isotopes. Nature, 188, 384-387 (1960).) (see Table I below).

The compound itself and/or its immediate surroundings will absorb the energy from the radiation. This energy excites the molecules, which can break up or react with other species or compounds. The excited molecular fragments may also react with other labeled compounds producing impurities. Energy absorbed by the immediate surroundings (mainly the solvent) can also produce reactive species, often free radicals, which can subsequently cause destruction of the molecules of radiolabeled compound. Whilst this is occurring, chemical decomposition often takes place as well, as these reactions occur in solution where chemical stability is known to be far more limited.

Secondary Decomposition

This is commonly the greatest path for the decomposition of radiochemicals, and it arises from the interaction of, for example, free radicals created by the radiation energy, with surrounding molecules including the radiolabeled molecules. It is by far the most difficult mode of decomposition to control and it is easily influenced by tiny changes to the environmental conditions. The low chemical content of radiolabeled compounds, particularly at high specific activity, amplifies the problems.

Secondary Decomposition in Water Solutions

The action of ionizing radiation on water is well documented (Thomas, J. K., Elementary processes and reactions in the radiolysis of water. Advances in Radiation Chemistry, 1, 103-198 (1969)). Ionization is known to occur along paths of the beta particles in discrete compartments known as “spurs” (Collison, E. and Swallow, A. J., The action of ionizing radiations on organic compounds. Quarterly Reviews of the Chemical Society, 9, 311-327 (1955)). The most damaging of the reactive species believed to be formed is thought to be the hydroxyl radical (Evans, E. A., Tritium and its Compounds. 2nd edition, Butterworths, London, pp. 642-782 (1974)). This was supported by the hydroxylation reaction of carbon-14 or tritium-labeled phenylalanine, to produce tyrosine and dihydroxyphenylalanine (Waldeck, B., [3H]Dopa in [3H]tyrosine with high specific activity. Journal of Pharmacy and Pharmacology, 23, 64-65 (1971)). In order to lower the decomposition, it is necessary to avoid or lessen the interactions between the damaging radicals and the surrounding molecules including the radiolabeled molecules. This can be achieved by lowering the temperature, diluting the radioactive concentration, and by adding radical scavengers. Ethanol is a common radical scavenger (typically as a 2% solution in water).

Secondary Decomposition in Organic Solvents

The detailed mechanism of decomposition of radiochemicals in organic solvents is not well known, and is expected to be complex. The effect of radiation energy on organic solvents is expected to be very different than that of aqueous media and would produce different forms of reactive species. The chemical purity of the solvent is for sure a critical parameter and well purified or very high quality purchased solvents ought to be used. The presence of peroxide in the solution may cause total destruction of the surrounding molecules including the radiolabeled molecules.

[18F]-Radiolabeled Aromatic Amino Acid

Radiolabeled aromatic amino acid derivatives, such as 18F-FDOPA, 18F-FTYR, 18F-FmTYR, etc. are often used to monitor the metabolism in the dopaminergic system. These radiotracers can be indicated to monitor Parkinson disease (PD), Alzheimer disease (AD) and some neurodegenerative diseases. These radiotracers have also shown interest in medical imaging of neuroendocrine tumors (NET).

Radiolabeled aromatic amino acid derivatives can be synthesized following different methods or paths such as for example:

However, most of these syntheses show drops in the radiochemical yields at high level of radioactivity due to the instability of the benzylic and/or phenolic radiosynthetic intermediates.

›PROBLEM TO BE SOLVED

Benzylic and Phenolic Radiosynthetic Intermediates

The instability toward radioactivity and especially beta and gamma radiations may be attributed to the presence of the aromatic ring (see above reactivity toward hydroxyl radicals), but also to the benzylic or phenolic positions that are present whatever the synthesis path (as shown above) chosen for radiolabeled aromatic amino acid synthesis.

These reactive sites can be subjected to side reactions that will consume the radiosynthetic intermediates, including cold intermediates such as the precursor to be radiolabelled, that become unavailable for the subsequent chemistry steps. This is detrimental for having high radiosynthesis yields in the radiopharmacies where starting activity is in the range of 1-30 Ci, i.e. radioactivity concentrations from 0.5 to 15 Ci/ml.

Document WO 2005/061415 A1 discloses the preparation of a resin-bound benzylic intermediate (example 13). This compound is used as an intermediate in the synthesis of 18F-labeled FDOPA (example 11). 2,2,6,6-tetramethylpiperidin-1-yl)oxidanyl (TEMPO) is used as a stabilizing agent. In this context ascorbate is also known to be a free radical trap.

›AIM OF THE INVENTION

The present invention aims at avoiding decomposition reactions, i.e. radiolysis resulting from high radioactivity concentrations, of radiosynthetic intermediates used in the synthesis of 18 F labeled aromatic amino acids by the use of radical scavengers or reductants or antioxidants during the crucial steps of the radiochemical synthesis. In other words, the invention aims at stabilizing the radiochemical yields of radiochemical synthesis of aromatic amino acids whatever the level of starting radioactivity used.

›DISCLOSURE OF THE INVENTION

The present invention relates to the stabilization toward radiolysis of radiosynthetic intermediates, including cold intermediates such as the precursor to be radiolabelled, by the use of radical scavengers or reductants or antioxidants during the steps where high radioactivity concentrations are involved. The decomposition is especially important when water is present, where the presence of highly reactive hydroxyl radicals decomposes the radiosynthetic intermediates.

The present invention focuses on radiosynthetic intermediates involved in the synthesis of 18 F radiolabeled aromatic amino acids derivatives, including cold molecules such as the prescursor to be radiolabelled, because of the instability of the aromatic ring and of the benzylic and phenolic species involved in these syntheses.

The general structure of the radiosynthetic intermediates that needs to be stabilized in the context of the present invention can be as follows:

with R 1 , R 2 , R 3 , R 4 , R 5 and L as follows:

R 1 , R 2 , R 3 , R 4 ═H, OMe, OBn, Oallyl, H, OH; L=NO 2 , NMe 3 + , F, 18 F, IO 2

and

R 5 ═OH, I, Br, Cl

Due to the side reactions that are involved during the decomposition of the radiosynthetic intermediates, the “stabilizer” used during the radiosynthetic process according to the present invention can either be:

a radical scavenging species; a reductant species; an antioxidant species; a species with more than one of the characteristics above.

In some preferred embodiments of the present invention, carbonate (CO 3 2− ), nitrite, thiosulfate, thiosulfite, phosphate, phosphite or hypophosphite is used for the stabilization of the radiosynthetic intermediate.

In some preferred embodiments of the present invention, phosphorous acid is used for the stabilization of the radiosynthetic intermediate.

In some preferred embodiments of the present invention, a Fe(II) derivative or a Sn(II) derivative is used for the stabilization of the radiosynthetic intermediate.

In some preferred embodiments of the present invention, a phenol derivative is used for the stabilization of the radiosynthetic intermediate.

In some preferred embodiments of the present invention, iodide is used for the stabilization of the radiosynthetic intermediate.

In some preferred embodiments of the present invention, the compound used for the stabilization is also involved in the radiosynthetic process as a reagent or as a solvent.

In some preferred embodiments of the present invention, HI is used as for the stabilization of the radiosynthetic intermediate but also as a reagent and can be involved in chemical reactions such as halogenation or hydrolysis/deprotection.

In some preferred embodiments of the present invention, toluene is used for as a solvent for the stabilization of the radiosynthetic intermediate.

In some preferred embodiments of the present invention, dichloromethane is used for as a solvent for stabilization of the radiosynthetic intermediate.

›EXAMPLES

In these examples it will be demonstrated how the right choice of the additives and reagents allows to stabilize the yields toward increasing the starting activity.

›Examples8
›Example 1

[18F]-FDOPA Synthesis with Lemaire et al. Method and with Eliminating HI in the Crucial Step

HI was used for the halogenation and is eliminated by KOH+water rinsing step during the on cartridge process. HI was also used during the deprotection/hydrolysis step.

Low activity (˜100 mCi) yield EOS: 30% (n=18). High activity (˜6 Ci) yield EOS: 3% (n=6).

›Example 2

[ 18 F]-FDOPA Synthesis with Lemaire et al. Method with HI

HI was used for the halogenation and remains present all the time during the on cartridge process. HI was also used during the deprotection/hydrolysis step.

Low activity (˜100 mCi) yield EOS: 25% (n=20). High activity (˜6 Ci) yield EOS: 25% (n=10).

›Example 3

[18F]-FDOPA Synthesis with Lemaire et al. Method with Replacement of HI with HBr in the Crucial Step

HBr was used for the halogenation HI was used during the deprotection/hydrolysis step.

Low activity (˜100 mCi) yield EOS: 20% (n=3). High activity (˜3 Ci) yield EOS: 12% (n=2).

›Example 4

[18F]-FDOPA Synthesis with Lemaire et al. Method with Replacement of HI with HBr/KI in the Crucial Step

HBr was used for the halogenation in mixture with KI. HI was used during the deprotection/hydrolysis step.

Low activity (˜100 mCi) yield EOS: 21% (n=3). High activity (˜3 Ci) yield EOS: 19% (n=2).

›Example 5

[18F]-FDOPA synthesis with Di Magno et al. method and HBr

HBr was used during the deprotection/hydrolysis step.

Low activity (˜100 mCi) yield EOS: 18% (n=2). High activity (˜1.5 Ci) yield EOS: 9% (n=1).

›Example 6

[18F]-FDOPA Synthesis with Coenen et al. Method and HBr

HBr was used during the deprotection/hydrolysis step.

Low activity (˜60 mCi) yield EOS: 15% (n=1). High activity (˜3 Ci) yield EOS: 8% (n=1).

›Example 7

[18F]FDOPA Synthesis with Coenen et al. Method and HBr/KI

HBr/KI was used during the deprotection/hydrolysis step.

Low activity (˜50 mCi) yield: 12% (n=1). High activity (˜3 Ci) yield: 11% (n=1).

›Example 8

[18F]-FDOPA Synthesis with Lemaire et al. Method and with Eliminating HI in the Crucial Step in the Presence of Sodium Thiosulfate (STS)

HI was used for the halogenation and is eliminated by a sodium thiosulfate in water solution rinsing step during the on cartridge process. HI was also used during the deprotection/hydrolysis step.

Low activity (˜45 mCi) yield EOS: 23% (n=1). High activity (˜3 Ci) yield EOS: 19% (n=1).

›Tables in the description — 1
TABLE I — Mode of
decompositionCauseMethod of Control
PrimaryNatural isotopic decayNone for a given specific
(Internal)activity
PrimaryDirect interaction ofDilution of the labelled
(External)radioactive emissionmolecules
(alpha, beta or gamma)
with molecules of the
compound
SecondaryInteraction of excitedDilution of labelled
species with molecules ofmolecules; cooling to low
the compoundtemperatures; free radical
scavenging
Chemical andThermodynamic instabilityCooling to low
microbiologicalof compound and poortemperatures; removal of
choice of environmentharmful agents

Claims as granted

7 claims

Log in to read the claims of this application.

Log in to unlock

Classifications

5 codes
IPC · International Patent Classification
Section A — Human necessities
  • A61K51/04
Section C — Chemistry; metallurgy
  • C07C229/00
  • C07B63/04
  • C07C227/12
  • C07C227/18

Claim changes

Soon
Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this application are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoomOct 2015Jan 2016Apr 2016Jul 2016Oct 2016Jan 2017Apr 2017Jul 2017Oct 2017USPTOApplicantNon-final rejectionResponse after non-finalFinal rejectionResponse after final
USPTOApplicanthover for detail · click to open
Pendency
2.1 y
763 days filing → grant
Office actions
2
non-final + final
Responses
2
no RCE
Examiner
Patrick Lewis
art unit 1673 · TC 1600
Citations: 13 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Log in to unlock

Documents

Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.

Log in to unlock

Chain of title

⤢ drag to zoom20162018202020222024202620282030203220342036Owner 1
Titlehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.

Log in to unlock